ac07e4e9-fa65-49f2-9f83-f13cc8a169d3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V2+0.500
- MYC_TARGETS_V1+0.400
- MITOTIC_SPINDLE+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- NOTCH_SIGNALING+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- ANGIOGENESIS+0.100
- DNA_REPAIR+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- COAGULATION-0.400
- COMPLEMENT-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INFLAMMATORY_RESPONSE-0.400
- KRAS_SIGNALING_UP-0.400
- APOPTOSIS-0.300
- BILE_ACID_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696755 | — | — | 0.925 |
| 2 | BS_N6N147BY | Embryonal tumors | — | 0.907 |
| 3 | BS_K25F4J3V | ATRT | — | 0.901 |
| 4 | BS_5P1TN10Z | Embryonal tumors | — | 0.899 |
| 5 | TCGA-77-A5G6-01A-11R-A27Q-07 | — | cohortSQ1 | 0.899 |
| 6 | de19e3c1-3508-4c13-b2cf-7079ee934a55 | — | — | 0.897 |
| 7 | SJEPD030795_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.894 |
| 8 | SAMN03290940 | — | — | 0.893 |
| 9 | SAMN03290918 | — | — | 0.892 |
| 10 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |